It's been a great morning session for Legend Biotech investors, who saw their shares rise 2.0% to a price of $37.95 per share. At these higher prices, is the company still fairly valued? If you are thinking about investing, make sure to check the company's fundamentals before making a decision.
Legend Biotech Has Elevated P/B and P/E Ratios:
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. The company belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 26.07 and an average price to book (P/B) ratio of 3.53. In contrast, Legend Biotech has a trailing 12 month P/E ratio of -39.5 and a P/B ratio of 6.69.
Legend Biotech has moved -45.3% over the last year compared to 7.9% for the S&P 500 — a difference of -53.2%. Legend Biotech has a 52 week high of $69.24 and a 52 week low of $30.17.
An Excellent Current Ratio but Negative Cash Flows:
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue (k) | $59,980 | $75,000 | $68,826 | $117,005 | $285,143 | $280,514 |
| Net Margins | -169% | -355% | -586% | -381% | -182% | -28% |
| Net Income (k) | -$101,590 | -$266,373 | -$403,582 | -$446,349 | -$518,254 | -$77,989 |
| Earnings Per Share | -$0.51 | -$1.13 | -$1.43 | -$1.4 | -$1.47 | -$0.21 |
| EPS Growth | n/a | -121.57% | -26.55% | 2.1% | -5.0% | 85.71% |
| Free Cash Flow (k) | -$83,065 | -$223,005 | -$198,465 | -$201,281 | -$393,276 | $13,867 |
| Total Debt (k) | $9,586 | $5,238 | $120,462 | $260,932 | $281,328 | $291,559 |
| Current Ratio | 1.62 | 5.14 | 4.14 | 3.69 | 6.92 | 4.84 |
